China Medical Univ. PAK4 compound 12i

China Medical Univ. PAK4 compound 12i: sourced facts only. name: "Taken together, in vitro and in vivo results demonstrated that compound 12i possessed high drug potential as an inhibitor of PAK4 to inhibit the growth and metastasis of TNBC." [PMID:39427518]; target: "Taken together, in vitro and in vivo results demonstrated that compound 12i possessed high drug potential as an inhibitor of PAK4 to inhibit the growth and metastasis of TNBC." [PMID:39427518]; developer: "School of Pharmacy, Key Laboratory of Research and Development of Small Molecule Targeted Antitumor Drugs, China Medical University, Shenyang 110122, PR China." [PMID:39427518]; stage: "Notably, compound 12i could effectively inhibit triple-negative breast cancer (TNBC) growth with little toxicity in the MDA-MB-231 cell xenograft model." [PMID:39427518]